The ECHDC1 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the AGS human gastric adenocarcinoma cell line. This product features a pool of cells with targeted disruptions in the ECHDC1 gene, generated by transient expression of CRISPR/Cas9 ribonucleoproteins. As a polyclonal reagent, it captures a spectrum of loss-of-function edits, providing a genetically heterogeneous model that avoids the clonal artifacts associated with single-cell-derived knockouts. The disrupted ECHDC1 locus ablates expression of the ethylmalonyl-CoA decarboxylase enzyme, enabling researchers to dissect its metabolic functions within a cancer-relevant context.
AGS cells were originally isolated from a poorly differentiated gastric adenocarcinoma and exhibit adherent epithelial morphology. These cells express markers characteristic of gastric epithelium and retain malignant properties, including dysregulated proliferation and metabolic plasticity. As a model system, AGS cells are widely employed to study gastric cancer biology, tumor microenvironment interactions, and the metabolic adaptations that support tumor growth. Their gastric origin and adenocarcinoma phenotype make them particularly relevant for investigating how metabolic pathway alterations contribute to gastric cancer pathogenesis.
Encoded by the ECHDC1 gene, the mitochondrial enzyme ethylmalonyl-CoA decarboxylase catalyzes the irreversible conversion of ethylmalonyl-CoA to butyryl-CoA, a critical step in the oxidation of branched-chain fatty acids and the methionine salvage pathway. This reaction feeds butyryl-CoA into ??-oxidation, ultimately yielding acetyl-CoA and TCA cycle intermediates that fuel cellular energy production. Transcription of ECHDC1 is regulated by nuclear receptors such as PPAR-alpha and HNF4-alpha, which respond to dietary fatty acid availability. Within the mitochondrial matrix, ECHDC1 functionally interacts with ALDH1L2, a 10-formyltetrahydrofolate dehydrogenase linking one-carbon metabolism, and ECHS1, a short-chain enoyl-CoA hydratase. The enzyme operates downstream of propionyl-CoA carboxylase and methylmalonyl-CoA mutase in the propanoate metabolism network, collaborating with aldo-keto reductase family 1 member C1 to coordinate branched-chain fatty acid degradation.
Disruption of ECHDC1 in AGS cells impairs the decarboxylation of ethylmalonyl-CoA, leading to a potential accumulation of this metabolite and a reduction in butyryl-CoA production. This metabolic bottleneck disrupts branched-chain fatty acid oxidation, potentially altering lipid homeostasis and diminishing the supply of acetyl-CoA to the TCA cycle. Given that gastric cancer cells frequently rewire lipid and energy metabolism to sustain proliferation, the ECHDC1 knockout model provides a valuable tool for examining how loss of this enzyme affects mitochondrial function, metabolic flux, and cellular energetics. This model is particularly relevant for studying metabolic vulnerabilities in gastric adenocarcinoma and for assessing whether ECHDC1 represents a targetable node in cancer metabolism.
Researchers can employ this polyclonal knockout population in a range of downstream applications, including western blot and RT-qPCR to verify ECHDC1 disruption and monitor downstream gene expression changes. Functional assays such as fatty acid oxidation measurements and LC-MS-based metabolite profiling allow detailed characterization of shifts in ethylmalonyl-CoA, butyryl-CoA, and TCA cycle intermediates. Cell proliferation assays and mitochondrial stress tests further reveal the impact of ECHDC1 loss on gastric cancer cell growth and bioenergetic capacity. This model is suited for validating ECHDC1’s role in mitochondrial metabolism, screening chemical modulators of branched-chain fatty acid oxidation, and exploring therapeutic targets in gastric cancer metabolic rewiring. For further technical details, please contact Ascent Research.
